MediciNova Inc. expected to Report Fiscal Year 2009 Results on March 30, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).

MediciNova Inc. reported un-audited consolidated earning results for the third quarter and nine months ended September 30, 2009. For the quarter ended September 30, 2009, MediciNova reported a net loss and net loss applicable to common stockholders of $4.8 million, or $0.40 basic and diluted loss per share, compared to a net loss and net loss applicable to common stockholders of $4.8 million, or $0.40 basic and diluted loss per share, for the same period last year. There were no revenues for the quarters ended September 30, 2009 and 2008. Research and development expenses were $2.4 million for the quarter ended September 30, 2009, compared to $3.5 million for the quarter ended September 30, 2008. Operating loss was $4.943 million against $5.697 million of previous year period. For the nine months ended September 30, 2009, net loss and net loss applicable to common stockholders was $14.453 million or $1.20 basic and diluted loss per share compared to net loss and net loss applicable to common stockholders of $ 20.510 million or $1.70 basic and diluted loss per share for the same period a year ago. Operating loss was $15.153 million against $18.816 million of previous year period.

MediciNova Inc. and the Hercules Market of the Osaka Securities Exchange announced the initiation of a Phase Ib clinical trial, by holding the Investigator's Meeting, to evaluate the safety of MN-221 at planned escalating doses in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). COPD exacerbations represents the second respiratory indication for which MediciNova is currently evaluating MN-221. This randomized, placebo-controlled, dose escalation Phase Ib clinical trial designed to evaluate the safety of MN-221 for the treatment of COPD exacerbations will involve approximately 48 stable, moderate to severe COPD patients. Each patient will receive a one-hour intravenous infusion of MN-221 at one of three escalating dose levels or placebo. Safety and preliminary efficacy data will be collected and summarized, but will not be subjected to inferential statistical analysis.